TITLE

Sandoz to build bulk drug plant at Mahad

PUB. DATE
June 2005
SOURCE
Chemical Business;Jun2005, Vol. 19 Issue 6, p78
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the plan of Sandoz Inc. to build an active pharmaceutical ingredients facility in Maharashtra, India. Features of the drug plant; Effort of Sandoz to strengthen its international production of drugs; Business operations of the company.
ACCESSION #
17868000

 

Related Articles

  • Sandoz Inc.  // Chain Drug Review;9/26/2011, Vol. 33 Issue 16, p80 

    The article profile Sandoz Inc., a global leader in generic medications and biosimilars with a significant growth through product launches including immunosuppressants, oncology injectables, and oral contraceptives.

  • New Construction in Pharmaceutical Manufacturing. Boswell, Clay // Chemical Market Reporter;6/18/2002, Vol. 259 Issue 25, pFR 19 

    Reports on the plants constructed by pharmaceutical companies to increase its capacity worldwide. Mergers of pharmaceutical companies; Production and research units built by Schering-Plough in Singapore; Project of Wyeth-Ayerst in Ireland.

  • Update.  // Medical Marketing & Media;Jul2006, Vol. 41 Issue 7, p15 

    The article offers news briefs related to pharmaceutical industry in the U.S. as of July 2006. Sandoz Inc. cannot use a reminder advertisement for its generic bupropion hydrochloride extended-release tables because the drug's lable contain a black box warning on suicidality. Food and Drug...

  • Novartis Matches in the Generic Drug Market.  // China Chemical Reporter;3/26/2005, Vol. 16 Issue 9, p10 

    The article reports that Novartis Corp. has announced the strategic acquisition of two leading generic drug companies that will be integrated into its Sandoz Inc. This would enable it to become the world leader in the generic drug industry. According to the projections from Novartis Corp., the...

  • Biogeneric Approved In Japan.  // Chain Drug Review;7/20/2009, Vol. 31 Issue 12, p112 

    The article reports that Samdoz has received marketing authorization for its first Japanese biosimilar, recombinant human growth hormone somatropin in Holzkirchen, Germany. It mentions that the firm is dedicated in broadening access to innovative and affordable biopharmaceuticals not only in...

  • Cryovac plans site for non-PVC medical film. Pryweller, Joseph // Plastics News;9/9/2002, Vol. 14 Issue 28, p23 

    Reports the operation of plant for polyolefin pharmaceutical films by Sealed Air Corp. in Duncan, South Carolina. Significance of plant to global health concerns; Impact of plant operation on major bag producers; Equipment and supplies of the facility.

  • DSM targets plants in Europe. Milmo, Sean // Chemical Market Reporter;04/13/98, Vol. 253 Issue 15, p5 

    Reports on DSM NV's plans to build fine chemicals plants in Europe, to help push up sales of the company's pharmaceutical subsidiaries.

  • BASF invests in multi-product unit. Whitfield, Mark // European Chemical News;6/2/2003, Vol. 78 Issue 2055, p38 

    Reports that Badische Anilin und Soda-Fabrik's fine chemicals division is expanding its facilities for the production of active pharmaceutical ingredients at its Minden, Germany site in 2003. Factor behind the site selection.

  • Novartis to Build Biotechnology Plant. Milmo, Sean // Chemical Market Reporter;01/24/2000, Vol. 257 Issue 4, p8 

    Reports that Novartis company plans to build a biotechnology plant in Huningue, Alsace, France, for the commercial production of anti-immunoglobulin E (IgE) for the treatment of asthma and allergies. Construction cost; Supplier of the cultures for the Huningue facility.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics